Yes correct.
That is the key here, as I and many others have had the realisation along the way and stated in the past:
An FDA approval on Ryoncil for aGVHD means that the FDA have generally endorsed Mesoblast’s Stem Cell therapeutic platform of development and treatment.
This in turn further de-risks EVERYTHING Mesoblast is developing in their pipeline. EVERYTHING
All financial institutional analysts then need to not only value aGVHD but also start to value higher the treatments and likely of approval of EVERYTHING that Mesoblast have in their pipeline.
Ann: FDA Accepts Mesoblast's BLA Resubmission for Remestemcel-L, page-943
-
- There are more pages in this discussion • 65 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
96.0¢ |
Change
-0.010(1.03%) |
Mkt cap ! $1.096B | |||
| Open | High | Low | Value | Volume |
| 98.0¢ | 98.5¢ | 95.0¢ | $2.617M | 2.715M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 107932 | 95.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 96.0¢ | 34142 | 1 |
View Market Depth
| Last trade - 16.10pm 13/08/2024 (20 minute delay) ? |
| MSB (ASX) Chart |